Quantitative IgG antibody test - SARS-CoV-2 – new
The SARS-CoV-2 IgG antibody test is used to verify the presence of immune antibodies following infection with the virus causing COVID-19. IgG antibodies can be detected at least 11 days after the onset of disease symptoms. IgG antibodies are a “late phase” p/c indicating the development of a specific humoral immune response that produces antibodies to SARS-CoV-2. A positive result may indicate a history of inactive infection.
We are now offering a quantitative IgG – SARS-CoV-2 assay (a chemiluminescent immunochemical test using paramagnetic particles for the quantitative determination of IgG antibodies to SARS-CoV-2 in human serum (blood-based assays)). This test may be performed prior to vaccination to check serum IgG antibody levels in the individual, and after vaccination to check the body’s immune response to the vaccine (according to vaccine manufacturers, full immunity will develop in most vaccinated persons 7-14 days after the second dose of the vaccine).
Call and make an appointment for testing:
Interpretation of the result:
Quantitative IgG antibody test -SARS-CoV-2
Unit: IU/mL
Range:
< 10 IU/mL – non-reactive > 10 IU/mL – reactive
Ref: <10 IU/mL
What does the test result mean?
A reactive test result means that the body has or has had previous exposure to SARS-COV-2 or has developed an immune response to the vaccine and has produced antibody to SARS-COV-2.
A non-reactive test result means that antibody to SARS-COV-2 was not found in the sample.
A non-reactive result may occur in infected individuals or after vaccination if the specimen collection is too early in the course of the disease and the body has not had enough time to develop antibodies to SARS-COV-2.
If symptoms are present, consult a physician for testing of SARS-COV-2 RNA with real time RT-PCR.
